TrialNet: Diabetes Type 1 Prevention

TrialNet：1 型糖尿病预防

• 批准号: 9066681
• 负责人: PETER A GOTTLIEB
• 金额: $ 58.72万
• 依托单位: UNIVERSITY OF COLORADO DENVER
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2019-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9066681
• 关键词: Ancillary Study; Autoimmune Diseases; Autoimmune Process; B-Lymphocytes; Biological Markers; Blood Glucose; C-Peptide; Clinical; Clinical Research; Conduct Clinical Trials; Development; Diabetes Mellitus; Dietary Intervention; Disease; Disease Progression; Enrollment; Functional disorder; Future; Goals; Health; Healthcare Systems; Human; Immune; Immune Tolerance; Immunologics; Immunotherapy; Insulin-Dependent Diabetes Mellitus; Intervention; Knowledge; Metabolic; Participant; Pathogenesis; Physicians; Populations at Risk; Prevention; Productivity; Protocols documentation; Recruitment Activity; Scientist; Study Subject; T-Lymphocyte; United States; Work; cost; human subject; impaired glucose tolerance; improved; monocyte; next generation; prevent

DESCRIPTION (provided by applicant): Multiple treatments that can change the course of type 1 diabetes have been identified over the last several years through the efforts of TrialNet, the Immune Tolerance Network and others. Although these immune therapies can stop disease progression in those with elevated blood sugars, the effect has proven to be transient in most study subjects. The ongoing effort of Type 1 Diabetes TrialNet, its Clinical Centers and affiliates is to continue to develop better therapies to prevent and reverse type 1 diabetes in human subjects. The Barbara Davis Center and its affiliate network has been a central contributor to these efforts from the beginning of DPT-1 through TrialNet and we hope with renewal of our Clinical Center to be able to continue to push towards these aims as well as develop the next generation of physician-scientists who can build on the work accomplished so far. Our aim is not only to conduct excellent clinical research which can answer the main study questions being examined: most often metabolic - development of impaired glucose tolerance, overt diabetes or reduced C-peptide, but also to develop immune biomarkers which can help us better understand the pathogenesis of disease progression and identify secondary markers of responder groups that allow us to better tailor our therapies to achieve successful prevention of T1D.

描述（由申请人提供）：在过去几年中，通过TrialNet、免疫耐受网络等的努力，已经确定了多种可以改变1型糖尿病病程的治疗方法。虽然这些免疫疗法可以阻止血糖升高患者的疾病进展，但在大多数研究对象中，这种效果被证明是短暂的。1型糖尿病试验网、其临床中心和附属机构正在努力 是继续开发更好的治疗方法来预防和逆转人类受试者的1型糖尿病。芭芭拉·戴维斯中心及其附属网络一直是这些努力的核心贡献者，从DPT-1开始到TrialNet，我们希望随着我们临床中心的更新，能够继续推动这些目标，并培养下一代的医生科学家，他们可以在迄今为止完成的工作的基础上再接再厉。我们的目标不仅是进行优秀的临床研究，可以回答正在研究的主要研究问题：最常见的是代谢-葡萄糖耐量受损，明显的糖尿病或C肽减少，还可以开发免疫生物标志物，帮助我们更好地了解疾病进展的发病机制，并确定反应组的次要标志物，使我们能够更好地定制我们的治疗，以实现成功的治疗。预防T1 D